RadNet’s Quantib B.V. Subsidiary Receives FDA Clearance for its Quantib Prostate™ 3.0 Software
01 Maio 2023 - 7:00AM
RadNet, Inc., (NASDAQ: RDNT) today announced that it has received
FDA clearance for the third-generation release of its Quantib
Prostate™ 3.0 MRI artificial intelligence (AI) software, further
enhancing the offering with new and updated tools. Quantib
Prostate™ software for MRI reading support was first introduced in
the US, followed by a class IIb CE marking in Europe in 2021.
Quantib Prostate™ 3.0: An AI Software for Prostate MRI
Reading and Reporting
Quantib Prostate™ 3.0 is a state-of-the-art AI-based software
solution that advances the MRI prostate reporting workflow and its
output for radiologists and urologists. It provides a suite of
tools that improve reporting quality and speed, including AI-based
segmentations and volumetry, PSA density calculation, precise
registration and movement correction, one-click segmentation of
lesion candidates, PI-RADS scoring support, and standardized
reporting to facilitate easy and comprehensive communication of
results.
The FDA 510k special clearance introduces a major upgrade to the
latest Quantib Prostate 2.1 release. The upcoming release of the
product will include an improved prostate and sub-region
segmentation algorithm, automated drawing of the lesions on the
PI-RADS sector map, and other functionalities that will enhance the
user experience.
“We are excited to present this update of Quantib Prostate™,
which enables us to continue to support our customers with the
newest developments and improved AI algorithm performance. We
strive to regularly and continuously improve our software in order
to support radiologists and urologists in the best possible way,”
said Arthur Post Uiterweer, CEO of Quantib.
“The approval of Quantib Prostate™ 3.0 represents another step
forward in advancing prostate cancer care by bringing the latest in
AI technology to MRI interpretation. With the increasing
recognition of the important role MRI plays in prostate cancer
diagnosis, we believe physicians will value the power that this
software puts in their hands,” said Gregory Sorensen, M.D.,
President of RadNet’s AI Division.
About Quantib B.V.
Quantib B.V., a wholly owned subsidiary of RadNet, Inc.,
provides AI radiology solutions to enable faster and more accurate
diagnosis by quickly identifying abnormalities, supporting adequate
and timely patient care. Using state-of-the-art artificial
intelligence technology, Quantib’s software advances the diagnostic
pathway by providing FDA cleared and CE marked solutions related to
neurodegeneration and prostate cancer. All solutions are deployed
through the Quantib AI Node platform, enabling seamless workflow
integration and rapid regulatory clearance. For more information,
visit www.quantib.com.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding,
fixed-site diagnostic imaging services in the United States based
on the number of locations and annual imaging revenue. RadNet has a
network of 357 owned and/or operated outpatient imaging centers.
RadNet's markets include California, Maryland, Delaware, New
Jersey, New York, Florida and Arizona. In addition, RadNet provides
radiology information technology and artificial intelligence
solutions, teleradiology professional services and other related
products and services to customers in the diagnostic imaging
industry. Together with affiliated radiologists, and inclusive of
full-time and per diem employees and technologists, RadNet has a
total of over 9,000 employees. For more information, visit
http://www.radnet.com.
Forward Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events
and trends. Forward-looking statements can generally be identified
by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,”
“believe,” “project,” “estimate,” “expect,” “strategy,” “future,”
“likely,” “may,” “should,” “will” and similar references to future
periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Because forward-looking
statements relate to the future, they are inherently subject to
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
Our actual results and financial condition may differ materially
from those indicated in the forward-looking statements. Therefore,
you should not place undue reliance on any of these forward-looking
statements.
CONTACTS:
Quantib B.V.Ory Six, Marketing Director+31 10
841 1749, o.six@quantib.com
RadNet, Inc.Mark StolperExecutive Vice
President & Chief Financial Officer310-445-2800
RadNet (NASDAQ:RDNT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
RadNet (NASDAQ:RDNT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024